{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:32:37Z","timestamp":1794335557356,"version":"4.9.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.diabet.2018.12.001","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T23:29:08Z","timestamp":1546558148000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":282,"title":["Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials"],"prefix":"10.1016","volume":"45","author":[{"given":"V.R.","family":"Aroda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"J\u00f3dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.diabet.2018.12.001_bib0005","first-page":"S1","article-title":"Standards of Medical Care in Diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.12.001_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","article-title":"Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis","volume":"137","author":"Khunti","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2018.12.001_bib0015","unstructured":"Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2018\/02\/WC500243464.pdf; 2018 [accessed 31 May 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0020","unstructured":"Menke A, Knowler WC, Cowie CC. Physical and metabolic characteristics of persons with diabetes and prediabetes. Chapter 9. In: Diabetes in America, 3rd ed. Cowie CC, et al. Eds. Bethesda: MD, National Institutes of Health; 2017: 9\u201314."},{"key":"10.1016\/j.diabet.2018.12.001_bib0025","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.diabet.2018.12.001_bib0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2337\/dc16-0509","article-title":"Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial","volume":"39","author":"Wing","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.12.001_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","article-title":"Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study","volume":"368","author":"Booth","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2018.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0055","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0060","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0070","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0075","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0080","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0090","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2018.12.001_bib0095","unstructured":"Eli Lilly Press Release., https:\/\/investor.lilly.com\/node\/39796\/pdf; 2018 [accessed 31 May 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0100","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2337\/diacare.23.7.962","article-title":"Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies","volume":"23","author":"Lee","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.12.001_bib0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0115","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.12.001_bib0120","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.diabet.2018.12.001_bib0125","unstructured":"Novo Nordisk A\/S. Novo Nordisk Receives FDA Approval of OZEMPIC\u00ae (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes, http:\/\/press.novonordisk-us.com\/2017-12-5-Novo-Nordisk-Receives-FDA-Approval-of-OZEMPIC-R-semaglutide-Injection-For-the-Treatment-of-Adults-with-Type-2-Diabetes; [accessed Mar 5, 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0130","unstructured":"Novo Nordisk A\/S. Ozempic\u00ae (semaglutide) approved in the EU for the treatment of type 2 diabetes, https:\/\/www.novonordisk.com\/bin\/getPDF.2167679. pdf; 2018 [accessed 31 May 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0135","unstructured":"Novo Nordisk Canada Inc. Ozempic\u00ae approved in Canada for the treatment of adults with type 2 diabetes, https:\/\/www.newswire.ca\/news-releases\/ozempic-approved-in-canada-for-the-treatment-of-adults-with-type-2-diabetes-668432133.html; 2018 [accessed 31 May 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0140","unstructured":"Novo Nordisk. Ozempic\u00ae approved in Japan for the treatment of type 2 diabetes, https:\/\/www.novonordisk.com\/bin\/getPDF.2178681.pdf [accessed 31\/05\/2018]."},{"issue":"Suppl 2","key":"10.1016\/j.diabet.2018.12.001_bib0145","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.2337\/dcS13-2015","article-title":"GLP-1 effects on islets: hormonal, neuronal, or paracrine?","volume":"36","author":"Donath","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.12.001_bib0150","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2018.12.001_bib0155","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.12.001_bib0160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.12.001_bib0165","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.12.001_bib0170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.12.001_bib0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.12.001_bib0180","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2018.12.001_bib0185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.12.001_bib0190","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.12.001_bib0195","unstructured":"US Department of Health and Human Services Food and Drug Administration. Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf; 2008 [accessed 31 May 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0200","doi-asserted-by":"crossref","unstructured":"Rodbard H, Bellary S, Hramiak I, Seino Y, Silver R, Bergan EQ, et al. Responder analysis of subjects achieving HbA1c \u22651% and weight loss \u22655% across SUSTAIN 1-5 clinical trials. ePoster number 802. Lisbon 2017 EASD, https:\/\/www.easd.org\/myeasd\/home.html#!resources\/responder-analysis-of-subjects-achieving-hba-sub-1c-sub-1-and-weight-loss-5-across-sustain-1-5-clinical-trials-86583438-fc4a-46b6-b123-8829251827b1; 2017 [accessed 31 May 2018].","DOI":"10.1016\/j.jcjd.2017.08.019"},{"key":"10.1016\/j.diabet.2018.12.001_bib0205","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.12.001_bib0210","article-title":"More semaglutide-treated subjects achieved HbA1c below 7.0% without weight gain, hypoglycaemia, and gastrointestinal adverse events vs. comparators in the SUSTAIN 1\u20135 trials","author":"DeVries","year":"2017","journal-title":"European Association for the Study of Diabetes (EASD) \u2013 53rd Annual Meeting"},{"key":"10.1016\/j.diabet.2018.12.001_bib0215","article-title":"Semaglutide reduces HbA1c across baseline HbA1c subgroups in the SUSTAIN 1\u20135 clinical trials","author":"Bain","year":"2017","journal-title":"77th Scientific Sessions of the American Diabetes Association"},{"key":"10.1016\/j.diabet.2018.12.001_bib0220","article-title":"The impact of gastrointestinal adverse events on weight loss with semaglutide in subjects with type 2 diabetes","author":"Atkin","year":"2017","journal-title":"European Association for the Study of Diabetes (EASD) \u2013 53rd Annual Meeting"},{"key":"10.1016\/j.diabet.2018.12.001_bib0225","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.12.001_bib0230","unstructured":"Intarcia Therapeutics press release. Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO Trial for ITCA 650, an investigational therapy for type 2 diabetes, https:\/\/www.intarcia.com\/media\/press-releases\/2016-may-6-cardiovascular-safety.html [Accessed October, 2017]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0235","article-title":"SGLT-2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","author":"Zelniker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2018.12.001_bib0240","unstructured":"Health Canada. OZEMPIC (semaglutide) injection product monograph, Jan 09, 2018, http:\/\/www.novonordisk.ca\/content\/dam\/Canada\/AFFILIATE\/www-novonordisk-ca\/OurProducts\/PDF\/ozempic-product-monograph.pdf; 2018 [accessed 31 May 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0245","unstructured":"US Food and Drug Administration. OZEMPIC (semaglutide) injection prescribing information; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf; 2017 [accessed 31 May 2018."},{"key":"10.1016\/j.diabet.2018.12.001_bib0250","unstructured":"Summary product characteristics Ozempic, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004174\/WC500244163.pdf [accessed April 2018]."},{"key":"10.1016\/j.diabet.2018.12.001_bib0255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.diabet.2017.12.009","article-title":"GLP-1 receptor agonists and cardiovascular protection: a class effect or not?","volume":"44","author":"Scheen","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2018.12.001_bib0260","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2018.12.001_bib0265","doi-asserted-by":"crossref","unstructured":"Vilsb\u00f8ll TG, Gumprecht J, Silver RJ, Hansen T, Pettersson J, Wilding J. Semaglutide treatment and renal function in the SUSTAIN 6 trial. 77th Scientific Sessions of the American Diabetes Association 2018 [Poster 1084-P].","DOI":"10.2337\/db18-1084-P"},{"key":"10.1016\/j.diabet.2018.12.001_bib0270","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diabet.2018.12.001_bib0275","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2042018814559725","article-title":"GLP-1 receptor agonists: a review of head-to-head clinical studies","volume":"6","author":"Trujillo","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.diabet.2018.12.001_bib0280","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/dom.13331","article-title":"Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials","volume":"20","author":"Warren","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.12.001_bib0285","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2018.12.001_bib0290","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.12.001_bib0295","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618302222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618302222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:55:24Z","timestamp":1761130524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363618302222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1262363618302222"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2018.12.001","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}